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Low molecular weight heparin treatment of acute moderate 
and severe pancreatitis: A randomized, controlled, 
open-label study
ABSTRACT
Background/Aims: Acute pancreatitis (AP) runs a moderately severe and severe course in 20%-30% of cases. The purpose of the pres-
ent study was to determine the effect of low molecular weight heparin (LMWH) for the prevention of pancreatic necrosis (PN) in moder-
ately severe and severe AP (MSAP).
Materials and Methods: A total of 100 patients with MSAP were randomized to receive either standard care (SC) or SC plus LMWH. 
LMWH was administered at 1 mg/kg via subcutaneous injection twice a day between days 1 and 7. The revised Atlanta criteria were used 
in the diagnosis of MSAP. Patients with a Harmless AP Score of ≥1 and a Balthazar computed tomography (CT) score of D and E were 
included in the study. 
Results: The mean age±SD of the patients (46 male and 54 female) was 52±19 years (range, 17-100). There were 50 patients in each 
group. On admission, clinical and laboratory parameters and Balthazar CT scores were similar between the groups. Initially, PN was 
present in one patient in the LMWH group and two in the SC group. Over the course, PN developed in 3 (6.1%) patients in the LMWH 
group and 11 (22.9%) in the SC group (p<0.05). Local and systemic complications were significantly lower in the LMWH group (p<0.05). 
No hemorrhagic complication occurred. Mortality was not significantly different between the groups (p=0.056). 
Conclusion: Low molecular weight heparin treatment is safe and provides better prognosis in MSAP.
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INTRODUCTION
Acute pancreatitis (AP) is a common disease with varying 
severity. Mild AP has an uneventful course with sponta-
neous recovery in <1 week. Moderately severe and severe 
AP (MSAP) is associated with local and systemic compli-
cations, notably, necrosis (sterile or infected) and organ 
failure (transient or persistent). Infected necrosis and 
persistent organ failure have poor prognosis. The begin-
ning and progression of AP is accompanied with systemic 
inflammatory cascade activation and a pancreatic micro-
circulatory disturbance that plays an important role in the 
pathogenesis of necrosis affecting not only the pancre-
as but also the kidneys, lungs, liver, and intestine in the 
course of severe AP (SAP) (1).
The exact pathogenesis of pancreatitis remains debat-
able, but it is probably closely related to the dysfunction 
of balance between proinflammatory and anti-inflamma-
tory responses. After premature activation of pancreatic 
proteases and extravasation of these activated digestive 
enzymes into the pancreas and peripancreatic tissues, cy-
tokines and other inflammatory mediators are produced 
and released with excessive leukocyte activation. They 
stimulate the inflammatory cascade, leading to systemic 
inflammatory response syndrome (2). Proinflammatory 
cytokines, such as tumor necrosis factor (TNF)-α and in-
terleukin (IL)-1β, IL-6, and IL-8, increase the capillary per-
meability with fluid loss, aggravating pancreatic injury (2). 
TNF-α damages the acinar cells and is probably respon-
sible for pancreatic necrosis (PN) and damage to other 
organs, such as lungs, liver, intestine, and spleen (3,4). 
Inflammatory substances, such as endothelin-1 (ET-1), 
nitric oxide, and other free radicals, damage the vascular 
endothelium, leading to microcirculatory disturbance and 
organ dysfunction (5). Anti-inflammatory cytokines, such 
as IL-10, cause immunosuppression, and its excess levels 
may increase the rate of infectious complications in the 
later stages of severe disease (6).
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The reported mortality rate in SAP is 7%-15% (7,8). The risk 
is higher in patients with persistent organ failure and infected 
necrosis. PN in itself is a severe complication and an import-
ant cause of death in AP; mortality rate can reach up to 10%-
23%(4). Therefore, prevention of PN or controlling its severity 
is the most important measure to decrease mortality in AP; 
however, we lack the effective means for this purpose.
Low molecular weight heparin (LMWH) has antithrombin 
activity and inhibits the inflammatory cascade by reduc-
ing the release of cytokines and inflammatory mediators. 
Moreover, heparin administration downregulates TNF-α-
induced leukocyte rolling (9), blocks the adhesion of leu-
kocytes to the endothelium by inhibiting the interactions 
between expressed adhesion molecules and endothelial 
cells (10), and reduces the activation of platelets (11) In ad-
dition, LMWH reduces the formation of microthrombi and 
improves microcirculation (12,13). Some experimental and 
clinical studies showed that treatment with heparin in-
hibits the development of ischemia/reperfusion-induced 
AP (14), ameliorates the severity of taurocholate-induced 
pancreatitis (15), and decreases the incidence of pancre-
atic encephalopathy (PE) (16). Recent clinical studies have 
shown that pre-procedural heparin administration signifi-
cantly reduces endoscopic retrograde cholangiopancrea-
tography (ERCP)-related pancreatitis (17). It improves the 
course of hypertriglyceridemia-induced AP (18) and may 
improve the prognosis in SAP (13,19).
The purpose of our study was to determine the efficacy 
of LMWH in the prevention of PN in MSAP in a random-
ized, controlled and open-label fashion.
MATERIAL AND METHODS
This was a single-center, prospective, randomized con-
trolled study conducted in patients who were admitted 
to the emergency department with a diagnosis of AP 
over a period of 16 months. We included patients whose 
symptoms started within 24 h.
Study population
In the study period, a total of 322 patients were admitted 
with a diagnosis of AP. The diagnosis was based on the 
American College of Gastroenterology guideline with the 
presence of at least two of the following three: 1. char-
acteristic epigastric pain, 2. serum amylase value of more 
than three times the upper limit of normal, and 3. char-
acteristic findings of AP in imaging (20). All patients had 
both 1 and 2.
Moderately severe and severe acute pancreatitis was 
defined according to the revised Atlanta criteria. Mod-
erately severe AP is characterized by local complications 
(peripancreatic fluid collections and pancreatic and peri-
pancreatic necrosis) and/or transient organ failure (<48 
h). Severe AP is characterized by persistent organ failure 
(>48 h). Harmless AP Score (rebound tenderness on ab-
dominal examination and abnormal hematocrit and cre-
atinine levels, one point each) was calculated (21), and 
computed tomography (CT) results were classified ac-
cording to the Balthazar and Modified CT Severity Index 
(MCTSI) (22).
Exclusion criteria included the presence of chronic pan-
creatitis, hypersensitivity to LMWH or radiocontrast 
agents, pregnant or breast feeding, coagulation distur-
bances, and severe comorbidities (Charlson Comorbidity 
Index (CCI) score ≥5) (23).
According to power analysis based on the prediction of 
30% necrosis in MSAP and estimated reduction of risk of 
10% with LMWH, we calculated that 100 patients would 
be adequate to detect a significant difference between 
the groups. Therefore, we stopped enrollment after we 
reached this number.
Study design
Patients were randomized according to a computer gen-
erated randomization and assigned to either the SC or 
the LMWH group by the pharmacist of the department 
blinded to the study. Randomization was balanced with 
every four patients enrolled and stratified by center.
Treatment protocol
Patients in the SC group received intravenous (IV) fluids, 
analgesics, and antibiotics in case it was needed. Patients 
in the LMWH group received that of the SC, in addition 
to enoxaparin sodium 1 mg/kg twice daily (the recom-
mended dosage in deep vein thrombosis and pulmonary 
embolism), from admission until day 7 (inclusive) by sub-
cutaneous injection. Patients were closely monitored in 
the hospital.
Clinical parameters and study endpoints
The primary outcome measure was the development of 
PN according to contrast-enhanced CT examination. The 
secondary outcome measures were time to tolerate oral 
intake, development of complications (local complica-
tions, such as pseudocyst and walled-off necrosis, as well 
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as systemic complications, such as renal and pulmonary 
failure and cardiovascular and gastrointestinal compli-
cations), need for endoscopic and surgical interventions, 
length of hospital stay, and mortality.
Laboratory tests
The following parameters were monitored on admission 
and during the following 7 days: hematocrit, white blood 
cell count, serum amylase and lipase, calcium, creatinine, 
albumin, transaminases, bilirubin, C-reactive protein, 
blood glucose level, and international normalized ratio.
CT scores
Abdominal CT scans of all patients were performed at the 
time of hospital admission (in the first 12 h) and on day 7. 
AP severity was assessed using MCTSI. According to the 
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Table 1. Demographic data and basal prediction of AP severity by means of a CT scan of study patients
SC Group (n=50) LMWH Group (n=50) p
Mean age±SD (range) 52±20 (17-100) 51±16 (20-85) NS
Gender F:M, n 26:24 28:22 NS
Diabetes Mellitus, n (%) 9 (%18) 10 (20%) NS
Charlson comorbidity score 0.56±1.1 0.52±0.9 NS
Etiology, n (%)
Biliary 31 (62%) 24 (48%)
NS
Post ERCP 3 (6%) 1 (2%)
Hyperlipidemia 4 (8%) 4 (8%)
Alcohol 4 (8%) 2 (4%)
Drug/toxic 2 (4%) 6 (12%)
Idiophatic 6 (12%) 13 (26%)
Balthazar, n (%)
NS
Stage D 20 (40%) 23 (46%)
Stage E 30 (60%) 27 (54%)
Modified CTSI, n (%)
Moderate 48 (96%) 49 (98%)
Severe 2 (4%) 1 (2%)
SC: Standard care; LMWH: Low molecular weight heparin; ERCP: Endoscopic retrograde
cholangiopancreatography; CTSI: Computed tomography severity index; NS: Non-significant
Table 2. Evolution of Computed tomography graded severity from the first 12 hours to the 7th day in groups
Severity
At 12th hours
SC group LWMH group
Moderate Severe Total Moderate Severe Total
At 7th day n (%) n (%) n (%) n (%) n (%) n (%)
Mild 8 (16.6%) 0 8 (16%) 23 (46.9%) 0 23 (46%)
Moderate 29 (60.4%) 0 29 (58%) 23 (46.9%) 0 23(46%)
Severe 11 (23%) 2 (100%) 13 (26%) 3 (6.2%) 1 (100%) 4 (8%)
Total 48 (100%) 2 (100%) 50 (100%) 49 (100%) 1 (100%) 50 (100%)
SC: Standard care; LMWH: Low molecular weight heparin
MCTSI, scores between 0 and 2 indicated mild, 4 and 6 
moderate, and 8 and 10 severe AP (22). Patients with mild 
pancreatitis according to the MCTSI in initial CT were ex-
cluded from the study.
Ethics statement
All participants provided written consent for participation 
in the study. Approval for the study was obtained from 
the local ethics committee. All procedures were in accor-
dance with the ethical standards of the committee on 
human experimentation of our institution and the Dec-
laration of Helsinki.
Imaging technique and image analysis
Contrast-enhanced helical CT scans (collimation, 4×2.5 
mm; slice thickness, 5 mm; range of reconstruction, 5 
mm; section 64, Aquilion; Toshiba Medical Systems, To-
kyo) were obtained 65 s after the administration of 100 
mL Iohexol (Omnipaque 300) at a rate of 3 mL/s. All im-
ages were analyzed by a radiologist blinded to the clinical 
findings of the patients.
Data analysis
The Statistical Package for Social Sciences (SPSS) ver-
sion 22 software (IBM Corp.; Armonk, NY, USA) was used 
for statistical analyzes. Quantitative data were expressed 
as percentages and mean±standard deviation. Normally 
distributed parameters were compared using Student’s 
t-tests, and non-normally distributed parameters were 
compared using Mann-Whitney U tests. Qualitative data 
were compared using chi-square test. A p value <0.05 
was considered statistically significant.
RESULTS
A total of 325 patients were screened for inclusion in the 
study. However, 7 were pregnant, 212 had mild AP, 3 had 
comorbid conditions (CCI scores ≥5), and 3 did not pro-
vide consent for inclusion in the study. Figure 1 shows the 
process of enrollment and flowchart of randomization. 
One hundred patients (54% female and 46% male) with 
MSAP with a mean age of 52±19 (range: 17-100) years 
were included in the study. The etiology of AP was biliary 
in 55 patients, hypertriglyceridemia in 8, drug associated 
in 8, alcohol in 6, and post ERCP in 4. In 19 patients, the 
etiology remained idiopathic. Balthazar’s score was stage 
D and E in 43 and 57 patients, respectively, at admission. 
In the stratification of pancreatitis severity as determined 
by MCTSI, 97 patients were moderate AP, and 3 were 
severe AP at admission. Table 1 shows the demograph-
ic data and basal prediction of AP severity by means of 
CT scan of study patients. On admission, the clinical pa-
rameters and AP severity scores of the SC and the LMWH 
groups were similar (p>0.05). Endoscopic intervention 
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Table 3. Clinical outcomes of patients who received stan-










Length of hospital stay, 
mean days (range) (3-73)
11.8±12.5 7.8±3.4 0.13
(4-16)
CT changes, n (%)
Regression 8 (16%) 27 (54%) 0.017*
Progression 16 (32%) 3 (6%)
No change 26 (52%) 20 (40%)
Endoscopic/surgical
necrosectomy, n (%)
2 (4%) 1 (2%) 0.56
Mortality, n (%) 5 (10%) 0 (0%) 0.056
*p<0.05
SC: Standard care; CT: Computed tomography; LMWH: Low molecular 
weight heparin








17 (34%) 7 (14%) 0.019
Pancreatic necrosis 11 (22.9%) 3 (6.1%) 0.017
<30% 7 2
>30% 4 1
Pseudocyts 11 (22%) 4 (8%)
Walled of necrosis 6 (12%) 2 (4%)
Systemic 
complications, n (%)
37 (74%) 18 (36%) 0.001
Pleural effusion 33 (66%) 17 (34%) 0.001
Vascular complication 7 (14%) 1 (2%)
ARDS 8 (16%) 3 (6%)
Renal insufficiency 8 (16%) 3 (6%)
Multiorgan failure 5 (10%) 0
All complications, 
n (%)
37 (74%) 18 (36%) 0.001
SC: Standard care; LMWH: Low molecular weight heparin; ARDS: Acute 
respiratory distress syndrome
was required in 19 patients (11 from the SC and 8 from 
the LMWH groups).
In the SC group, there were 50 patients, with 24 males 
aged 17-100 (mean age: 53±21 years) years. According to 
the MCTSI, 48 (96%) patients had moderate, and 2 (4%) 
had severe pancreatitis at admission. In the follow-up, 
8 (16.6%) patients with moderate AP regressed to mild, 
29 (60.4%) had remained moderate, and 11 (23%) pro-
gressed to severe AP. Two patients who had severe AP 
initially remained so (Table 2).
In the LMWH group, there were 50 patients, with 22 
males aged 20-85 (mean age±SD: 51±17) years. Accord-
ing to the MCTSI, 49 (98%) patients had moderate, and 
1 (2%) patient had severe pancreatitis in the first 12 h. 
In the course of patients with moderate AP, 23 (46.9%) 
regressed to mild, 23 (46.9%) remained moderate, and 
3 (6.2%) progressed to severe AP. One patient who had 
severe AP initially remained so (Table 2). In moderate pa-
tients, the regression, as well as the progression, rates 
were significantly better in the LMWH group than in the 
SC group (p=0.002).
Time to tolerate oral intake was significantly lower in the 
LMWH group than in the SC group (2.7±1.5 vs. 7.1±12.2 
days; p=0.013). There was a trend for shorter hospi-
tal stay in the LMWH group, but the difference was not 
significant (7.8±3.4 vs. 11.8±12.5 days; p=0.13). Mortal-
ity was not statistically different between the groups (0 
[0%] vs. 5 [10%] for the LMWH and SC groups, respec-
tively; p=0.056 by Fisher’s exact test). Overall, compared 
with the SC group, regression at day 7 CT findings was 
significantly higher, and progression was significantly 
lower in the LMWH group (54% vs. 16% regression and 
6% vs. 32% progression for the LMWH and SC groups, 
respectively, p<0.05) (Table 3).
Overall, complications developed in 55 patients (18 in 
the LMWH and 37 in the SC groups). Local complications 
were significantly lower in the LMWH group than in the 
SC group (7 [14%] vs. 17 [34%]; p=0.019). PN was pres-
ent at the beginning in one patient in the LMWH group 
and 2 in the SC group. In the study period, PN developed 
significantly less frequently in the LMWH group (3 [6.1%] 
vs. 11 [22.9%] for the LMWH and SC groups, respectively; 
p<0.05). Systemic complications were significantly lower 
in the LMWH group than in the SC group (18 [36%] vs. 37 
[74%]; p=0.001) (Table 4). For the 5 patients who died, all 
from the SC group, mortality was due to acute respirato-
ry distress syndrome, septic shock, and multiorgan failure 
secondary to infected necrosis.
DISCUSSION
Acute pancreatitis runs a severe course in a minority of 
patients; however, this subset is responsible for the bur-
den of the disease. Therefore, decreasing the burden of 
AP can only be achieved with successful management 
strategies toward SAP.
Previous clinical and experimental data revealed that the 
fate of AP is dictated in the early hours of pancreatitis, and 
impairment of microcirculation is the pivotal derangement 
leading to necrosis. The presence of a hematocrit value 
>44% and failing to decrease it with IV fluid boluses is 
considered to predict severe prognosis. Hemoconcentra-
tion may be a cause for the impairment of microcirculation 
and may play an important role in the transition of edem-
atous to necrotizing pancreatitis. Abundance of several 
inflammatory cytokines in the microenvironment of the 
pancreas in the setting of AP is also a precipitating event 
(24). Proinflammatory cytokines, such as IL-1β, IL-6, and 
TNF-α, increase during the course of AP and are respon-
sible for the progression of microvascular disturbance. 
Microcirculatory disturbance is as important as enzymatic 
and free radical damage in the pathogenesis of AP.
Thrombosis, associated with denudation of endothelial 
cells, sludge formation, and resultant stasis, in the pan-
creatic circulation is an event as early as mucoid swelling 
in the acini in the course of AP. It starts from the periph-
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ery and extends toward the center. Fibrin accumulates at 
the distal part of the thrombus.
Enoxaparin is an LMWH that binds to and accelerates 
the activity of antithrombin III (ATIII). By activating ATIII, 
enoxaparin preferentially potentiates the inhibition of 
coagulation factors Xa and IIa. Factor Xa catalyzes the 
conversion of prothrombin to thrombin and prevent fi-
brin clot formation. The heparin-ATIII complex reduc-
es the activity of trypsin and chymotrypsin and inhibits 
trypsinogen activation (25). The anti-inflammatory prop-
erties of heparin are different from its anticoagulant ac-
tivity (26). Heparin reduces recruitment of inflammato-
ry cells into the site of injury and leucocyte adhesion to 
vascular endothelial cells (27). LMWH has been shown to 
downregulate ET-1, TNF-α, and IL-6, leading to the re-
duction of the formation of microthrombosis, improving 
microcirculation (28). Furthermore, heparin inhibits pan-
creatic enzymes and accelerates pancreatic regeneration 
during the course of the disease (14).
The treatment of AP is mainly supportive and relies on flu-
id and electrolyte replacement, pain control, nutrition, and 
antibiotic therapy, if necessary. Since we do not have spe-
cific treatment modalities aiming to prevent enzymatic and 
free radical damage, anticoagulation treatment appears to 
be the only means to limit acinar cell damage. Furthermore, 
preserving the patency of microcirculation would limit the 
extent of enzymatic and free radical damage. Since recanal-
ization follows shrinkage and cicatrization of vessels, reper-
fusion injury may have a role in the morphogenesis of AP, 
which is also prevented by anticoagulation treatment.
However, hemorrhage into the parenchyma resulting 
from microcirculatory paresis is inevitable ranging from 
minimal to massive in the form of diapedesis. Enoxapa-
rin may paradoxically prevent hemorrhage, preserving the 
patency of microcirculation.
There are experimental and clinical studies on the pro-
tective effect of heparin in the treatment of AP. Qiu et al. 
demonstrated the protective effect of LMWH on PE pro-
gression in rats with SAP. They reported that the sever-
ity of brain damage significantly decreases in the LMWH 
group (12). In another study, they showed that LMWH de-
creases TNF-α and ET-1 and has a positive effect on mor-
phological changes and vascular flow in rats with SAP (5). 
Lu et al. performed a randomized trial to study the ef-
fect of LMWH in the prevention of PE in 256 patients 
with SAP. The results indicated that LMWH markedly de-
creases the PE incidence and improves the survival rate in 
SAP (16). A clinical study conducted by Lu et al. showed 
that LMWH results in mortality reduction and improves 
CT score in patients with SAP (13). In a small study (17 
cases), Jiao et al. showed that LMWH decreases the white 
blood cell count and increases the arterial blood partial 
oxygen pressure of patients with AP (19).
In our study, we selected patients with moderately severe 
and severe pancreatitis because microcirculatory distur-
bance is, mostly, pronounced in this subset. However, 
since we did not encounter any untoward effect of hepa-
rin, it may be used in all cases.
As it appears from the present study, early administration of 
LMWH improved the radiological picture with regression in 
the majority. Progression occurred in only 3 (6%) patients. In 
the SC group, the radiological picture worsened in 1/3, and 
regression occurred in only 8 (16%) patients. Furthermore, 
most of the clinical parameters were better in the treat-
ment group, with lower rate of admission to the intensive 
care unit, time to oral feeding, hospital stay, and occurrence 
of necrosis. Actually, all these parameters are dependent to 
each other, and clinical course is dictated by the very early 
course of AP. Prevention of stasis in this phase by LMWH 
may be a very important measure to prevent ischemia/
reperfusion injury, including a free radical induced one. It ap-
pears that enzymatic injury is a reparable condition in case 
there is no significant impairment in microcirculation.
In conclusion, LMWH treatment is safe and provides bet-
ter prognosis in MSAP. Future multicenter trials on the 
effectiveness of LMWH should be undertaken in the very 
early course of AP.
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